3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
September is usually the weakest month for stocks, and this year too, the month has started under pressure from rising yields and geopolitical tens...
Genmab A/S (GMAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paradigm Biocapital Advisors Senai Asefaw | 13,133,131 | $360,767,109 | +65% | 6.76% |
| 2. | Orbis Investment Management William B. Gray | 11,368,161 | $312,283,383 | -13% | 1.07% |
| 3. | Deerfield Management James E. Flynn | 6,865,000 | $188,581,550 | +179% | 1.97% |
| 4. | Deep Track Capital David Kroin | 5,650,000 | $155,205,500 | +55% | 2.26% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 4,975,324 | $136,672,150 | 0.06% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 718,179 | $25,621,036 | 0.39% | |
| 2. | 99,937 | $3,565,253 | 0.78% | |
| 3. | 68,527 | $2,444,701 | 1.57% | |
| 4. | 41,520 | $1,481,217 | 0.01% | |
| 5. | 30,105 | $1,073,997 | 0.01% |
News See All
Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?
Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion.
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20).
3 ‘Perfect Ten’ Healthcare Stocks That Analysts Rate as a Strong Buy
We are diving into three healthcare stocks which all have a Strong Buy consensus and a 10 out of 10 TipRanks Smart Score. The Smart Score is a prop...
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks on our list. TheFly reported on July 2 that H.C.
10 Best Innovative Healthcare Stocks to Buy Now
In this article, we will be taking a look at the 10 Best Innovative Healthcare Stocks to Buy Now. The U.S.
10 Best Large Cap Stocks Under $30 With Highest Upside Potential
In this article, we will take a look at some of the best large cap stocks under $30 that are currently offering attractive upside potential.
8 Most Promising Biotech Stocks to Buy Now
In this article, we will discuss: 8 Most Promising Biotech Stocks to Buy Now.
Genmab (GMAB) Rated Outperform on Oncology Pipeline
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
Hedge Fund Resource Center